

ABIOMED INC
Form 4
May 12, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Greenfield Andrew J

(Last) (First) (Middle)

C/O ABIOMED, INC., 22 CHERRY
HILL DRIVE

(Street)

DANVERS, MA 01923

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
ABIOMED INC [ABMD]

3. Date of Earliest Transaction
(Month/Day/Year)
05/08/2015

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
__X__ Officer (give title ____ Other (specify
below) below)

VP Healthcare Solutions

6. Individual or Joint/Group Filing(Check
Applicable Line)
__X__ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, \$.01 par value	05/08/2015		M	22,881	A \$ 13.57	91,619	D
Common Stock, \$.01 par value	05/08/2015		S ⁽⁵⁾	4,322 ⁽⁵⁾	D \$ 64.1598 ⁽⁶⁾	87,297	D
Common Stock, \$.01 par value	05/08/2015		S ⁽⁵⁾	4,852 ⁽⁵⁾	D \$ 65.1294 ⁽⁷⁾	82,445	D

Edgar Filing: ABIOMED INC - Form 4

Common Stock, \$0.01 par value	05/08/2015	S ⁽⁵⁾	2,549 ⁽⁵⁾	D	\$ 66.3304 ⁽⁸⁾	79,896	D
Common Stock, \$0.01 par value	05/08/2015	S ⁽⁵⁾	6,506 ⁽⁵⁾	D	\$ 67.3335 ⁽⁹⁾	73,390	D
Common Stock, \$0.01 par value	05/08/2015	S ⁽⁵⁾	3,685 ⁽⁵⁾	D	\$ 67.8776 ⁽¹⁰⁾	69,705	D
Common Stock, \$0.01 par value	05/08/2015	S ⁽⁵⁾	870 ⁽⁵⁾	D	\$ 69.0306 ⁽¹¹⁾	68,835	D
Common Stock, \$0.01 par value	05/08/2015	S ⁽⁵⁾	97 ⁽⁵⁾	D	\$ 69.81 ⁽¹²⁾	68,738	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) ⁽¹⁾	\$ 13.57	05/08/2015		M		22,881		06/01/2007 ⁽²⁾	06/01/2016	Common Stock	22,881
Stock Option (right to	\$ 11.27							05/30/2008 ⁽²⁾	05/30/2017	Common Stock	0

buy) ⁽¹⁾

Stock Option (right to buy) ⁽¹⁾	\$ 13.8	05/23/2009 ⁽²⁾	05/23/2018	Common Stock	0
Stock Option (right to buy) ⁽³⁾	\$ 10.03	06/03/2011 ⁽²⁾	06/03/2020	Common Stock	0
Stock Option (right to buy) ⁽³⁾	\$ 22.44	05/22/2013 ⁽²⁾	05/22/2022	Common Stock	0
Stock Option (right to buy) ⁽³⁾	\$ 14.39	02/19/2014 ⁽²⁾	02/19/2023	Common Stock	0
Stock Option (Right to Buy) ⁽³⁾	\$ 23.15	05/14/2014 ⁽²⁾	05/14/2023	Common Stock	0
Stock Option (right to buy) ⁽³⁾	\$ 21.55	05/14/2015 ⁽⁴⁾	05/14/2024	Common Stock	0

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Greenfield Andrew J C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923			VP Healthcare Solutions	

Signatures

/s/ Stephen C. McEvoy (by power of attorney) 05/12/2015

^{__}Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant to reporting person of option to buy shares of Common Stock under ABIOMED, Inc. 2000 Stock Incentive Plan.
- (2) These options became exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.

Edgar Filing: ABIOMED INC - Form 4

- (3) Grant to reporting person of option to buy shares of Common Stock under ABIOMED, Inc. 2008 Stock Incentive Plan.
- (4) These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- (5) Sale of common stock pursuant to reporting owner's 10b5-1 plan.

(6) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$63.6200 and \$64.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(7) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$64.6200 and \$65.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(8) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$65.6750 and \$66.6500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(9) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$66.7000 and \$67.6900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(10) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$67.7000 and \$68.66000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(11) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$68.7000 and \$69.6900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(12) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$69.7000 and \$69.9600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.